Welcome to our dedicated page for Ispecimen SEC filings (Ticker: ISPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iSpecimen Inc. (ISPC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. iSpecimen’s filings offer detailed information about its online marketplace for human biospecimens, its capital structure, financing activities, governance, and interactions with The Nasdaq Capital Market. Stock Titan enhances these documents with AI-powered summaries designed to explain the key points of each filing in clear language.
For investors and analysts reviewing annual reports on Form 10-K and quarterly reports on Form 10-Q, iSpecimen’s disclosures describe its mission to accelerate life science research through a global biospecimen marketplace, its technology platform, and its classification as an emerging growth company and smaller reporting company. These periodic reports, when available, are central sources for understanding the company’s business model, risk factors, and operating environment.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings include a November 21, 2025 report describing a Nasdaq notice that the company’s closing bid price had fallen below the $1.00 minimum required under Listing Rule 5550(a)(2), along with the timeframe provided to regain compliance. Other 8-Ks detail leadership changes, such as the appointment of a new Chief Executive Officer and the addition of an independent director, and report the results of a special meeting of stockholders where proposals related to a reverse stock split, an increase in authorized shares, private financing approvals, amendments to convertible securities, and an equity line of credit were approved.
Proxy statements on Schedule 14A (DEF 14A) shed light on corporate governance, director elections, stock incentive plans, and the agenda for annual and special meetings. The 2025 special meeting proxy statement outlines proposals to adjust the company’s capital structure and financing flexibility, while the 2025 annual meeting proxy statement covers director elections, auditor ratification, and a new stock incentive plan.
iSpecimen’s registration statements on Form S-1 and S-1/A describe offerings of common stock and pre-funded warrants, the use of proceeds, and detailed background on the company’s marketplace model. These filings also incorporate discussion of the company’s corporate treasury plan related to the Solana blockchain ecosystem and associated risk factors, as noted in the explanatory notes to recent amendments.
On Stock Titan, users can review these ISPC filings as they are updated in real time from EDGAR, while AI-generated overviews highlight important elements such as capital-raising terms, listing compliance matters, governance proposals, and structural changes to outstanding securities. This combination of source documents and AI explanations helps readers navigate complex forms, from 10-Ks and 10-Qs to 8-Ks, S-1 registration statements, and proxy materials, and track how iSpecimen manages its biospecimen marketplace business within the public-company regulatory framework.
iSpecimen Inc. filed an amended current report to update the terms of its Series C Convertible Non-Voting Preferred Stock. On January 16, 2026, the company filed an Amended Certificate of Designation that modifies Section 7 of the original designation. The change makes both the Conversion Price and the Floor Price subject to proportionate adjustment if there is any reverse stock split, share combination or similar transaction that reduces the number of outstanding common shares.
The amendment was approved by the company and holders of more than a majority of the outstanding Series C Preferred Stock, as permitted under the original terms. All other rights, preferences and privileges of the Series C Preferred Stock remain unchanged.
iSpecimen Inc. reported that Nasdaq has notified the company its common stock no longer meets the Nasdaq Capital Market’s minimum bid price rule, which requires a closing bid of at least $1.00 per share for 30 consecutive business days. The stock will continue trading under the symbol ISPC with no immediate change to its listing status.
The company has until May 18, 2026, a 180‑day period, to regain compliance by having its closing bid price at or above $1.00 per share for at least ten consecutive business days, or up to twenty if required by Nasdaq staff. If compliance is not regained by that date, iSpecimen may qualify for an additional 180‑day period if it meets other Nasdaq listing criteria and may consider actions such as a reverse stock split. Failure to regain compliance within the applicable period could lead to delisting, though iSpecimen would have the right to appeal.
iSpecimen Inc. is asking stockholders to approve several items at its 2025 virtual annual meeting on December 31, 2025. Holders of common stock as of November 3, 2025, when 9,771,028 shares were outstanding, can vote online, by phone, or by mail.
Stockholders will vote on electing two Class I directors to three-year terms, ratifying Bush & Associates CPA LLC as independent auditor for 2025, and approving the new 2025 Stock Incentive Plan. The plan would reserve 1,000,000 shares of common stock for equity awards, supplementing the Amended and Restated 2021 Stock Incentive Plan, which had 73,084 shares available as of October 28, 2025. The board is also seeking authority to adjourn the meeting if needed and recommends voting “FOR” all proposals.
iSpecimen Inc. (ISPC) director Arphing Lee filed an initial Form 3 reporting their ownership position as of 11/07/2025. The filing states that no securities of iSpecimen Inc. are beneficially owned, meaning the director reports holding no shares or derivative securities of the company at this time. This is an administrative disclosure required for insiders when they assume a reportable role such as director.
iSpecimen Inc. reported weak results for the quarter ended September 30, 2025, with revenue of $106,592, down sharply from $2,661,936 a year earlier. Operating expenses of $2.94 million drove a quarterly net loss of $2,780,648 and a nine-month loss of $5,486,287, though losses narrowed versus 2024. Cash and cash equivalents were $2,782,758, against negative working capital of $2,096,503 and an accumulated deficit of $77,348,904, leading management to state that there is substantial doubt about the company’s ability to continue as a going concern.
To bolster liquidity, iSpecimen completed a $3,999,574 underwritten offering and a $1,749,998 private placement in 2025, plus prior ATM sales. The company has aggressively cut compensation and technology costs versus 2023–2024, but remains heavily loss-making. Legal matters include a $215,000 arbitration settlement with its former CIO and several ongoing disputes, including litigation with a technology vendor that briefly shut down the iSpecimen Marketplace and led to a court order requiring deposits of 15% of revenue into a dedicated account up to $420,000.
iSpecimen Inc. filed an amended proxy outlining its 2025 annual meeting, to be held virtually on December 31, 2025 at 10:00 a.m. Eastern Time. Holders of record at the close of business on November 3, 2025 may vote.
Stockholders will vote on: electing two Class I directors (Siyun Yang and Arphing (Tommy) Lee), ratifying Bush & Associates CPA LLC as independent auditor for the year ending December 31, 2025, approving the iSpecimen Inc. 2025 Stock Incentive Plan, and a proposal to adjourn the meeting if necessary.
The 2025 Stock Incentive Plan would reserve 1,000,000 shares for future equity awards, has no evergreen increase, and would become effective December 31, 2025, with a 10‑year term. As of October 28, 2025, 73,084 shares remained available under the existing 2021 plan. The Board unanimously recommends a vote “FOR” all proposals.
iSpecimen Inc. appointed Katharyn Field as Chief Executive Officer, Secretary, and Treasurer, effective immediately. She will continue to serve as President. On the same date, Robert Bradley Lim stepped down as CEO, Secretary, and Treasurer and resigned from the Board.
The Board filled the resulting vacancy by appointing Arphing (Tommy) Lee as an independent director and named him to the Audit Committee and the Nominating and Corporate Governance Committee. The company stated that, to its knowledge, Mr. Lim’s resignation did not involve a disagreement with the company, and it does not anticipate disruption to operations.
There were no changes to Ms. Field’s compensation in connection with this appointment. Committee compositions were updated, with Mr. Anthony Lau continuing as Audit Chair, Ms. Yuying Yang as Compensation Chair, and Mr. Avtar Dhaliwal as Nominating and Corporate Governance Chair.
iSpecimen Inc. reported voting results from its October 30, 2025 special meeting. Stockholders approved multiple capital actions, including a reverse stock split in a range of 1:10 to 1:100, an increase in authorized capital stock from 250,000,000 to 1,000,000,000, and approvals under Nasdaq Listing Rule 5635(d) for potential private financings and an equity line of credit that could exceed 19.99% of outstanding shares and occur below the Minimum Price.
As of the July 25, 2025 record date, 3,979,517 common shares were outstanding and entitled to vote. A quorum was present with 1,437,502 shares represented, approximately 36% of those entitled to vote. Stockholders also approved amending certain outstanding convertible securities to raise the conversion price floor from 50% to 80% of the lowest volume-weighted average price during the measurement period, and authorized other business properly brought before the meeting.
iSpecimen Inc. filed a universal shelf registration on Form S-3 to register up to $100,000,000 of securities, including common stock, preferred stock, debt securities, warrants, rights, and units. These may be offered and sold from time to time after effectiveness, with specific terms to be set by prospectus supplements.
Its common stock trades on Nasdaq as “ISPC.” The last reported sale price was $0.817 on October 20, 2025. The company cites an aggregate market value held by non‑affiliates of approximately $11,133,000, based on 9,771,028 shares and a $1.14 closing price on October 3, 2025. Under General Instruction I.B.6, primary offerings are limited to no more than one‑third of public float in any 12‑month period while the float remains below $75,000,000, and the company notes it has not sold securities under I.B.6 during the 12‑month period ending with this prospectus.
The prospectus also describes a planned corporate treasury program targeting up to $200,000,000 of Solana (SOL) acquisitions, with an initial financing targeted in Q4 2025, subject to market, regulatory, and corporate considerations, and details related risks, including volatility, regulatory uncertainty, custody/cybersecurity, liquidity for Locked SOL, and potential reputational impacts.
iSpecimen Inc. (ISPC) called a special shareholder meeting to approve several capital actions. The Board seeks authority to effect a reverse stock split at a ratio between 1-for-10 and 1-for-100, with the exact ratio set at the Board’s discretion, primarily to support compliance with Nasdaq’s $1.00 minimum bid price. The Board also asks to increase authorized capital from 250,000,000 to 1,000,000,000 shares.
The agenda includes two Nasdaq Listing Rule 5635(d) approvals: one for potential non‑public financings exceeding 19.99% of outstanding common stock or voting power (at a price that may be below the Minimum Price), and another to permit an equity line of credit with issuances that could also exceed 19.99%. Separately, the company seeks to amend certain outstanding convertibles to raise the conversion price floor from 50% to 80% of the lowest VWAP during the applicable period, which may reduce shares issuable upon conversion. An adjournment proposal is also included.
The Board recommends voting FOR all proposals. The meeting is virtual on October 30, 2025 at 10:00 a.m. ET for holders of record as of July 25, 2025.